Prof. Dr. Markus Rothenburger

• Direct report to CEO, member of the executive board, HC 120 FTE, 20 FTE US based; Heading Division of Medical & Regulatory Affairs (Reg Aff; Med Aff; PV; QA; DM & Biostat) • Biologics; rare diseases (orphan drugs); oncology; cardiovascular metabolics; hematology; infectious diseases; antivirals; sepsis; intensive Care; immunoglobulins; antibodies; hemostasiology; rheumatoid arthritis

• 2nd management line, HC 5 FTE, plus global matrix structure (100+); Heading global medical affairs • Nutrition; volume therapy; oncology; short bowel syndrome; rare diseases (orphan drugs); sepsis; inflammation; intensive care medicine; CKD; IBD; cardiovascular; metabolic syndrome

• Direct Report to CEO, HC 5 FTE + matrix structure Achievements - Implemented and managed a German branch - Set up a Medical Affairs department for Vifor Pharma Germany - Consulted a hospital contributing in cost savings by 1 Mio € annually - Built and maintained a reliable KOL network (DACH region) - Performed 3 trial rescues for phase I – III trials

• Reporting line to BU Head, HC 5 FTE • Transplantation, sepsis, infectious diseases, cardiovascular diseases, diabetes, metabolic syndrome; inflammation, immunology, oncology, respiratory failure, heart failure, immunosuppression

• Reporting to Head of department • Spearheaded the Intensive Care, Surgical and Transplant program

• Trained in General- and Thoracic Surgery Achievements - Spearheaded numerous missions in catastrophes, as well as war missions. - Planned and conducted a field hospital in Serbia.